@article{4336b536d4504f748e7031f0348c5b06,
title = "Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies",
abstract = "Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.",
author = "Cross, {Robert W.} and Mire, {Chad E.} and Branco, {Luis M.} and Geisbert, {Joan B.} and Rowland, {Megan M.} and Heinrich, {Megan L.} and Augustine Goba and Mambu Momoh and Grant, {Donald S.} and Mohamed Fullah and Khan, {Sheik Humarr} and Robinson, {James E.} and Geisbert, {Thomas W.} and Garry, {Robert F.}",
note = "Funding Information: This work was supported by Department of Health and Human Services/ National Institutes of Health / National Institute of Allergy and Infectious Diseases Challenge and Partnership Grant Numbers AI067188 and AI082119 , Health and Human Services Contract HHSN272200900049C, and National Institutes of Health / National Institute of Allergy and Infectious Diseases Grant Number R01AI104621 , UC7AI094660 for BSL-4 operations support of the Galveston National Laboratory, and RC-0013-07 from the Louisiana Board of Regents. ",
year = "2016",
month = sep,
day = "1",
doi = "10.1016/j.antiviral.2016.08.012",
language = "English (US)",
volume = "133",
pages = "218--222",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
}